- Report
- October 2023
- 190 Pages
Global
From €4737EUR$4,900USD£4,069GBP
- Report
- March 2023
- 653 Pages
Global
From €4786EUR$4,950USD£4,111GBP
- Report
- July 2020
- 452 Pages
Global
From €4786EUR$4,950USD£4,111GBP
- Report
- April 2020
- 305 Pages
Global
From €3384EUR$3,500USD£2,906GBP
- Report
- May 2018
- 124 Pages
Global
From €5752EUR$5,950USD£4,941GBP
- Report
- January 2019
- 97 Pages
Global
From €3867EUR$4,000USD£3,322GBP
- Report
- February 2023
- 264 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- February 2024
- 168 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- February 2024
- 129 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- May 2022
- 210 Pages
Global
From €5577EUR$5,769USD£4,791GBP
The Transcatheter Valve Replacement (TVR) market is a subset of the Cardiovascular Devices market. It is a minimally invasive procedure used to replace a diseased or damaged heart valve. The procedure involves inserting a catheter into the patient's body and guiding it to the heart, where the new valve is then deployed. The procedure is less invasive than traditional open-heart surgery, and is often used to treat patients who are at high risk for complications from open-heart surgery.
TVR is a rapidly growing market, with new technologies and procedures being developed to improve patient outcomes. The market is expected to continue to grow as more patients are able to benefit from the procedure.
Some of the companies in the TVR market include Edwards Lifesciences, Medtronic, Boston Scientific, Abbott, and St. Jude Medical. Show Less Read more